Abstract 467P
Background
Lung cancer is a serious problem and one of the most common cancer diseases worldwide. Many studies were shown that free-circulating mtDNA levels are increased in the serum/plasma of patients with various malignancies. Here we analysed mtDNA levels in the plasma of patients with NSCLC compared to the health individuals.
Methods
68 patients with NSCLC and 59 healthy individuals were recruited for this study. A quantitative analysis of the free-circulating mtDNA was conducted using the qPCR. To create a standard curve, the purified PCR product of the 490 bp mtDNA fragment was used. The DNA concentration determined using the PicoGreen dsDNA Quantification Kit. The copy number of the free-circulating mtDNA was calculated according to the protocol of Applied Biosystems.
Results
The levels of free-circulating mtDNA in patients with NSCLC were found in range from 2.7x1010 to 6,51x1014 with a mean value 3,04x1013 copies/μL. In plasma samples of healthy subjects the levels of mtDNA copies were found to range from 6,0x109 to 1,73x1013 with a mean value 7,46x1011. Thus, the levels of free-circulating mtDNA in patients with NSCLC were higher in 6.6 times than in those of healthy subjects (P < 0.05).
Conclusions
Results of this study suggest that high free-circulating mtDNA copies number is a promising marker for diagnosis and prediction of non-small cell lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Authors.
Funding
Ministry of Education and Science of the Republic of Kazakhstan (grant no. 1258/GF4).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract